Amedeo Smart

Free Medical Literature Service



Chronic Heart Failure

  Free Subscription

Articles published in
Am Heart J
    September 2021
  1. TROMP J, Ouwerkerk W, Cleland JGF, Chandramouli C, et al
    A Global Perspective of Racial Differences and Outcomes in Patients Presenting with Acute Heart Failure.
    Am Heart J. 2021 Sep 10. pii: S0002-8703(21)00228.
    >> Share

    August 2021
  2. BILCHICK KC, Stafford P, Laja O, Elumogo C, et al
    Relationship of Ejection Fraction and Natriuretic Peptide Trajectories in Heart Failure with Baseline Reduced and Mid-Range Ejection Fraction.
    Am Heart J. 2021 Aug 25. pii: S0002-8703(21)00220.
    >> Share

    July 2021
  3. MOGHADDAM N, Malhi N, Toma M
    Impact of Oral Soluble Guanylate Cyclase Stimulators in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Am Heart J. 2021 Jul 17. pii: S0002-8703(21)00182.
    >> Share

  4. NUNEZ-GIL IJ, Olier I, Feltes G, Viana-Llamas MC, et al
    Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
    Am Heart J. 2021;237:104-115.
    >> Share

    June 2021
  5. JENSEN J, Omar M, Moller JE, Schou M, et al
    Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial".
    Am Heart J. 2021;236:106.
    >> Share

  6. PATOULIAS D, Papadopoulos C, Doumas M
    Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
    Am Heart J. 2021;236:104-105.
    >> Share

    May 2021
  7. FUDIM M, Spates T, Sun JL, Kittipibul V, et al
    Early Diuretic Strategies and the Association With In-Hospital and Post-Discharge Outcomes in Acute Heart Failure.
    Am Heart J. 2021 May 27. pii: S0002-8703(21)00140.
    >> Share

  8. KITTIPIBUL V, Blumer V, Hernandez GA, Fudim M, et al
    Pre-operative Atrial Fibrillation and Early Right Ventricular Failure after Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.
    Am Heart J. 2021 May 23. pii: S0002-8703(21)00138.
    >> Share

  9. RODRIGUES DOS SANTOS M, Alves MNN, Jordao CP, Pinto CEN, et al
    Sacubitril/Valsartan Versus Enalapril on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction: A Randomized, Double-Blind, Active-Controlled Study: Sacubitril/Valsartan and Enalapril on Peak VO2 in Patients with Heart Failur
    Am Heart J. 2021 May 13. pii: S0002-8703(21)00125.
    >> Share

  10. CHEN Y, Lawrence J, Stockbridge N
    Days Alive Out of Hospital in Heart Failure: Insights from the PARADIGM-HF and CHARM Trials.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00119.
    >> Share

  11. GRUBB CS, Truby LK, Topkara VK, Bohnen MS, et al
    Advanced Heart Failure Patients Supported with Ambulatory Inotropic Therapy: What Defines Success of Therapy?
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00121.
    >> Share

  12. LEE DS, Straus SE, Austin PC, Mohamed S, et al
    Rationale and Design of the Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial: A Stepped Wedge Cluster Randomized Trial.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00123.
    >> Share

  13. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    >> Share

  14. SINGH JP, Walsh MN, Kubo SH, Auricchio A, et al
    Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial.
    Am Heart J. 2021;235:158-162.
    >> Share

  15. AHMED I, Merchant FM, Curtis JP, Parzynski CS, et al
    Impact of insurance status on ICD implantation practice patterns: Insights from the NCDR ICD registry.
    Am Heart J. 2021;235:44-53.
    >> Share

    April 2021
    Letter to the Editor by Mehmood regarding the article "Outcomes and Cost Among Medicare Beneficiaries Hospitalized for Heart Failure Assigned to Accountable Care Organizations".
    Am Heart J. 2021;234:132.
    >> Share

    March 2021
  17. ALFREDSSON J, James SK, Erlinge D, Herlitz J, et al
    Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex related outcomes from DETO2X-AMI.
    Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00066.
    >> Share

  18. BROOKSBANK JA, Greene SJ, Harris HM, Stebbins A, et al
    Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
    Am Heart J. 2021;233:1-4.
    >> Share

    February 2021
  19. SHAHZEB KHAN M, Kristensen SL, Vaduganathan M, Kober L, et al
    Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00054.
    >> Share

  20. RO O, Qr Y, A E, P A, et al
    Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00055.
    >> Share

  21. JENTZER JC, Ahmed AM, Vallabhajosyula S, Burstein B, et al
    Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time.
    Am Heart J. 2021;232:94-104.
    >> Share

    January 2021
  22. ALBERT NM, Tyson RJ, Hill CL, DeVore AD, et al
    Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbiditie
    Am Heart J. 2021 Jan 23. pii: S0002-8703(21)00028.
    >> Share

  23. R P, G W, J R, M T, et al
    A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00016.
    >> Share

  24. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    >> Share

  25. ISRAR MZ, Bernieh D, Salzano A, Cassambai S, et al
    Association of gut-related metabolites with outcome in acute heart failure.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00010.
    >> Share

  26. ADACHI Y, Yamamoto M, Shimura T, Yamaguchi R, et al
    Late kidney injury after transcatheter aortic valve replacement.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00011.
    >> Share

  27. YERASI C, Tripathi B, Wang Y, Forrestal BJ, et al
    National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016.
    Am Heart J. 2021;231:25-31.
    >> Share

    December 2020
  28. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    >> Share

  29. SARRAJU A, Li J, Cannon CP, Chang TI, et al
    Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
    Am Heart J. 2020 Dec 20. pii: S0002-8703(20)30407.
    >> Share

  30. VAISHNAV J, Hubbard A, Chasler JE, Lepley D, et al
    Management of Heart Failure in Cardiac Amyloidosis Using an Ambulatory Diuresis Clinic.
    Am Heart J. 2020 Dec 19. pii: S0002-8703(20)30411.
    >> Share

  31. NUCCIA M, Claudia M, Alice S, Guido T, et al
    Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: rationale and design of the randomized Altshock- 2 trial.
    Am Heart J. 2020 Dec 15. pii: S0002-8703(20)30399.
    >> Share

    November 2020
  32. HAMO CE, Fonarow GC, Greene SJ, Vaduganathan M, et al
    Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure.
    Am Heart J. 2020 Nov 29. pii: S0002-8703(20)30397.
    >> Share

  33. RASLAN IR, Ross HJ, Fowler RA, Scales DC, et al
    The Associations Between Direct and Delayed Critical Care Unit Admission with Mortality and Readmissions Among Patients with Heart Failure.
    Am Heart J. 2020 Nov 6. pii: S0002-8703(20)30369.
    >> Share

    October 2020
  34. COX ZL, Collins SP, Aaron M, Hernandez GA, et al
    Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30357.
    >> Share

  35. BOAS R, Thune JJ, Pehrson S, Kober L, et al
    Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30359.
    >> Share

  36. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    >> Share

  37. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    >> Share

  38. FRIEDMAN DJ, Emerek K, Kisslo J, Sogaard P, et al
    Left bundle branch block is associated with a similar Dyssynchronous phenotype in heart failure patients with Normal and reduced ejection fractions.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30338.
    >> Share

  39. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    >> Share

  40. PARADIES V, Zheng H, Bulluck H, Hausenloy DJ, et al
    Response to the letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:117-118.
    >> Share

  41. ROSSBERG N, Kirresh A, Ahmad M
    Letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:116.
    >> Share

    September 2020
  42. BLUMER V, Greene SJ, Ortiz M, Kittipibul V, et al
    In-hospital outcomes after bariatric surgery in patients with heart failure.
    Am Heart J. 2020 Sep 26. pii: S0002-8703(20)30260.
    >> Share

  43. MENTZ RJ, Xu H, O'Brien EC, Thomas L, et al
    PROVIDE-HF primary results: Patient-reported outcomes inVestigation following initiation of drug therapy with Entresto (Sacubitril/valsartan) in heart failure.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30265.
    >> Share

  44. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    >> Share

  45. TAKADA S, Kondo T, Yasunaga M, Watanabe S, et al
    Early rehabilitation in older patients hospitalized with acute decompensated heart failure: A retrospective cohort study.
    Am Heart J. 2020 Sep 18. pii: S0002-8703(20)30262.
    >> Share

  46. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    >> Share

    August 2020
  47. VENECHUK G, Khazanie P, Page RL, Knoepke CE, et al
    An electronically delivered, patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial.
    Am Heart J. 2020 Aug 28. pii: S0002-8703(20)30243.
    >> Share

  48. HONIGBERG MC, Pirruccello JP, Aragam K, Sarma AA, et al
    Menopausal Age and Left Ventricular Remodeling by Cardiac Magnetic Resonance Imaging Among 14,550 Women.
    Am Heart J. 2020 Aug 19. pii: S0002-8703(20)30235.
    >> Share

  49. BERRY N, Mauri L, Feldman T, Komtebedde J, et al
    Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).
    Am Heart J. 2020;226:222-231.
    >> Share

    July 2020
  50. JENSEN J, Omar M, Kistorp C, Poulsen MK, et al
    Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
    Am Heart J. 2020;228:47-56.
    >> Share

  51. BHARDWAJ B, Cohen DJ, Vemulapalli S, Kosinski AS, et al
    Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry.
    Am Heart J. 2020;228:57-64.
    >> Share

  52. OLSEN CR, Mentz RJ, Anstrom KJ, Page D, et al
    Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure.
    Am Heart J. 2020;229:1-17.
    >> Share

    June 2020
  53. ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Martinez-Amezcua P, Cabello-Lopez A, et al
    A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study).
    Am Heart J. 2020;227:31-39.
    >> Share

  54. VAN OORT S, Beulens JWJ, van Ballegooijen AJ, Handoko ML, et al
    Modifiable lifestyle factors and heart failure: A Mendelian randomization study.
    Am Heart J. 2020;227:64-73.
    >> Share

  55. JOSEPH P, Dokainish H, McCready T, Budaj A, et al
    A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.
    Am Heart J. 2020;227:56-63.
    >> Share

    May 2020
  56. KUNO T, Takahashi M, Obata R, Maeda T, et al
    Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City.
    Am Heart J. 2020 May 15. pii: S0002-8703(20)30141.
    >> Share

  57. LUO N, Hammill BG, DeVore AD, Xu H, et al
    Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations.
    Am Heart J. 2020;226:13-23.
    >> Share

  58. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    >> Share

  59. KAHN PA, Riello RJ 3rd, Ahmad T, Desai NR, et al
    Adoption of sacubitril-valsartan in the Medicare population.
    Am Heart J. 2020;223:81-83.
    >> Share

  60. FUDIM M, Dalgaard F, Al-Khatib SM, J Friedman D, et al
    Future research prioritization in cardiac resynchronization therapy.
    Am Heart J. 2020;223:48-58.
    >> Share

    April 2020
  61. BILCHICK KC, Wang Y, Curtis JP, Cheng A, et al
    Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
    Am Heart J. 2020;222:93-104.
    >> Share

    March 2020
  62. WU CM, Albert NM, Gluckman TJ, Lu D, et al
    Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program.
    Am Heart J. 2020;224:77-84.
    >> Share

  63. PARADIES V, Zheng H, Chan MHH, Chan MYY, et al
    Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.
    Am Heart J. 2020;224:1-9.
    >> Share

  64. NAPOLI C, Benincasa G, Donatelli F, Ambrosio G, et al
    Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics.
    Am Heart J. 2020;224:113-128.
    >> Share

    February 2020
  65. MENTZ RJ, DeVore AD, Tasissa G, Heitner JF, et al
    PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
    Am Heart J. 2020;223:98-105.
    >> Share

  66. COOPER LB, Psotka MA, Sinha S, Nallamothu BK, et al
    Specificity of administrative coding for older adults with acute heart failure hospitalizations.
    Am Heart J. 2020;223:1-2.
    >> Share

    January 2020
  67. DUENGEN HD, Kim RJ, Zahger D, Orvin K, et al
    Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
    Am Heart J. 2020;224:129-137.
    >> Share

  68. UDELSON JE, Lewis GD, Shah SJ, Zile MR, et al
    Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved
    Am Heart J. 2020;222:183-190.
    >> Share

  69. ARASHI H, Sato T, Kobashigawa J, Luikart H, et al
    Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.
    Am Heart J. 2020;222:30-37.
    >> Share

  70. LEERINK JM, Feijen ELAM, van der Pal HJH, Kok WEM, et al
    Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study.
    Am Heart J. 2020;219:89-98.
    >> Share

  71. LU DY, Ventoulis I, Liu H, Kudchadkar SM, et al
    Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy.
    Am Heart J. 2020;219:58-69.
    >> Share

  72. YAO X, McCoy RG, Friedman PA, Shah ND, et al
    ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial.
    Am Heart J. 2020;219:31-36.
    >> Share

    December 2019
  73. ELMING MB, Hammer-Hansen S, Voges I, Nyktari E, et al
    Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI.
    Am Heart J. 2019 Dec 24. pii: S0002-8703(19)30351.
    >> Share

  74. KALRA R, Shenoy C
    Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?
    Am Heart J. 2019 Dec 17. pii: S0002-8703(19)30352.
    >> Share

  75. LOEB M, Dokainish H, Dans A, Palileo-Villanueva LM, et al
    Corrigendum to "Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design" [212 (2019) 36-44].
    Am Heart J. 2019 Dec 12. pii: S0002-8703(19)30323.
    >> Share

  76. TRIPOLT NJ, Kolesnik E, Pferschy PN, Verheyen N, et al
    Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Am Heart J. 2019;221:39-47.
    >> Share

    November 2019
  77. FUDIM M, Kelly JP, Jones AD, AbouEzzeddine OF, et al
    Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
    Am Heart J. 2019;220:97-107.
    >> Share

  78. LORING Z, Shrader P, Allen LA, Blanco R, et al
    Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
    Am Heart J. 2019;219:21-30.
    >> Share

    October 2019
  79. SLEE A, Saksena S
    Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial.
    Am Heart J. 2019;220:1-11.
    >> Share

  80. JENTZER JC, Baran DA, van Diepen S, Barsness GW, et al
    Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients.
    Am Heart J. 2019;219:37-46.
    >> Share

  81. DEVORE AD, Granger BB, Fonarow GC, Al-Khalidi HR, et al
    Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF.
    Am Heart J. 2019;220:41-50.
    >> Share

  82. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    >> Share

  83. CZOBOR P, Hung YY, Baer D, McGlothlin D, et al
    Amyloid cardiomyopathy in a large integrated health care system.
    Am Heart J. 2019;216:42-52.
    >> Share

    September 2019
  84. HORNE BD, Roberts CA, Rasmusson KD, Buckway J, et al
    Risk score-guided multidisciplinary team-based Care for Heart Failure Inpatients is associated with lower 30-day readmission and lower 30-day mortality.
    Am Heart J. 2019;219:78-88.
    >> Share

  85. UNNI RR, Lee SF, Thabane L, Connolly S, et al
    Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trial.
    Am Heart J. 2019;220:116-126.
    >> Share

  86. VAN MOURIK Y, Rutten FH, Bertens LCM, Cramer MJM, et al
    Clinical research study implementation of case-finding strategies for heart failure and chronic obstructive pulmonary disease in the elderly with reduced exercise tolerance or dyspnea: A cluster randomized trial.
    Am Heart J. 2019;220:73-81.
    >> Share

  87. FERREIRA JP, Rossignol P, Dewan P, Lamiral Z, et al
    Income level and inequality as complement to geographical differences in cardiovascular trials.
    Am Heart J. 2019;218:66-74.
    >> Share

    August 2019
  88. BHATT AS, Luo N, Solomon N, Pagidipati NJ, et al
    International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Am Heart J. 2019;218:57-65.
    >> Share

  89. PIOTROWICZ E, Piotrowicz R, Opolski G, Pencina M, et al
    Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial-Study design and description of the intervention.
    Am Heart J. 2019;217:148-158.
    >> Share

    July 2019
  90. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    >> Share

  91. ADAMO M, Grasso C, Capodanno D, Rubbio AP, et al
    Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry.
    Am Heart J. 2019;217:32-41.
    >> Share

    June 2019
  92. HALL TS, von Lueder TG, Zannad F, Rossignol P, et al
    Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.
    Am Heart J. 2019;215:83-90.
    >> Share

  93. GALLI E, Hubert A, Le Rolle V, Hernandez A, et al
    Myocardial constructive work and cardiac mortality in resynchronization therapy candidates.
    Am Heart J. 2019;212:53-63.
    >> Share

    May 2019
  94. CLAEYS MJ, Coussement P, Dubois P, Garcia-Dorado D, et al
    Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial.
    Am Heart J. 2019 May 30. pii: S0002-8703(19)30129.
    >> Share

  95. LINDENFELD J, Abraham WT, Maisel A, Zile M, et al
    Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF).
    Am Heart J. 2019;214:18-27.
    >> Share

    April 2019
  96. WARRAICH HJ, Allen LA, Blue LJ, Chaussee EL, et al
    Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation: An analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for
    Am Heart J. 2019;213:91-96.
    >> Share

  97. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    >> Share

  98. YANDRAPALLI S, Sanaani A, Harikrishnan P, Aronow WS, et al
    Cardiogenic shock during heart failure hospitalizations: Age-, sex-, and race-stratified trends in incidence and outcomes.
    Am Heart J. 2019;213:18-29.
    >> Share

  99. WANG A, Chu VH, Athan E, Delahaye F, et al
    Association between the timing of surgery for complicated, left-sided infective endocarditis and survival.
    Am Heart J. 2019;210:108-116.
    >> Share

    March 2019
  100. EDMONSTON DL, Wu J, Matsouaka RA, Yancy C, et al
    Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients.
    Am Heart J. 2019;212:101-112.
    >> Share

  101. LOEB M, Dokainish H, Dans A, Palileo-Villanueva LM, et al
    Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.
    Am Heart J. 2019;212:36-44.
    >> Share

  102. LECLERCQ C, Burri H, Curnis A, Delnoy PP, et al
    Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP-PHASE II).
    Am Heart J. 2019;209:1-8.
    >> Share

    January 2019
  103. SHARMA A, Mentz RJ, Granger BB, Heitner JF, et al
    Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial.
    Am Heart J. 2019;211:22-33.
    >> Share

  104. ZIAEIAN B, Hernandez AF, DeVore AD, Wu J, et al
    Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry.
    Am Heart J. 2019;211:1-10.
    >> Share

  105. ALVI RM, Afshar M, Neilan AM, Tariq N, et al
    Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.
    Am Heart J. 2019;210:39-48.
    >> Share

    December 2018
  106. SANDHU AT, Heidenreich PA
    Comparison of the change in heart failure readmission and mortality rates between hospitals subject to hospital readmission reduction program penalties and critical access hospitals.
    Am Heart J. 2018;209:63-67.
    >> Share

  107. BURSTEIN DS, Shamszad P, Dai D, Almond CS, et al
    Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults.
    Am Heart J. 2018;209:9-19.
    >> Share

    November 2018
  108. CANEPA M, Ameri P, Lucci D, Nicolosi GL, et al
    Modes of death and prognostic outliers in chronic heart failure.
    Am Heart J. 2018;208:100-109.
    >> Share

  109. GEENEN LW, Baggen VJM, Koudstaal T, Boomars KA, et al
    The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach.
    Am Heart J. 2018;208:91-99.
    >> Share

  110. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    >> Share

    September 2018
  111. BENCHETRIT L, Zimmerman C, Bao H, Dharmarajan K, et al
    Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates.
    Am Heart J. 2018;207:19-26.
    >> Share

  112. Home monitoring with IT-supported specialist management versus home monitoring alone in patients with heart failure: Design and baseline results of the SUPPORT-HF 2 randomized trial.
    Am Heart J. 2018;208:55-64.
    >> Share

    August 2018
  113. COLIN-RAMIREZ E, Ezekowitz JA
    Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF).
    Am Heart J. 2018;205:87-96.
    >> Share

  114. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    >> Share

    July 2018
  115. MILLER PE, Ahmad T
    Loop diuretics in heart failure: Few facts and lots of prejudice.
    Am Heart J. 2018 Jul 30. pii: S0002-8703(18)30234.
    >> Share

  116. FUDIM M, Loungani R, Doerfler SM, Coles A, et al
    Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial.
    Am Heart J. 2018;204:163-173.
    >> Share

  117. FUDIM M, O'Connor CM, Mulder H, Coles A, et al
    Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.
    Am Heart J. 2018 Jul 29. pii: S0002-8703(18)30233.
    >> Share

  118. MORICI N, Oliva F, Ajello S, Stucchi M, et al
    Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30217.
    >> Share

  119. MENTZ RJ, O'Connor CM, Granger BB, Yang H, et al
    Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30219.
    >> Share

  120. KETEYIAN SJ, Kerrigan DJ, Lewis B, Ehrman JK, et al
    Exercise training workloads in cardiac rehabilitation are associated with clinical outcomes in patients with heart failure.
    Am Heart J. 2018;204:76-82.
    >> Share

  121. KOROL S, White M, O'Meara E, Tournoux F, et al
    A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30203.
    >> Share

  122. DAUBERT MA, Whellan DJ, Woehrle H, Tasissa G, et al
    Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial.
    Am Heart J. 2018;201:40-48.
    >> Share

  123. UPADHYA B, Brubaker PH, Morgan TM, Eggebeen JD, et al
    The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial.
    Am Heart J. 2018;201:164-167.
    >> Share

    June 2018
  124. ARNOLD SV, Echouffo-Tcheugui JB, Lam CS, Inzucchi SE, et al
    Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
    Am Heart J. 2018;203:25-29.
    >> Share

  125. BALLING L, Thomsen JH, Wolsk E, Hassager C, et al
    Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise.
    Am Heart J. 2018 Jun 14. pii: S0002-8703(18)30172.
    >> Share

  126. AHMAD FS, French B, Bowles KH, Sevilla-Cazes J, et al
    Incorporating patient-centered factors into heart failure readmission risk prediction: A mixed-methods study.
    Am Heart J. 2018;200:75-82.
    >> Share

  127. LUO N, Ballew NG, O'Brien EC, Greiner MA, et al
    Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
    Am Heart J. 2018;200:134-140.
    >> Share

  128. JALNAPURKAR S, Zhao X, Heidenreich PA, Bhatt DL, et al
    A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.
    Am Heart J. 2018;200:127-133.
    >> Share

  129. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    >> Share

  130. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    >> Share

    May 2018
  131. MCALISTER FA, Youngson E, van Diepen S, Ezekowitz JA, et al
    Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study.
    Am Heart J. 2018 May 27. pii: S0002-8703(18)30164.
    >> Share

  132. SHAKIR M, Wasfy JH
    Heart failure and readmissions: Research in the public eye.
    Am Heart J. 2018;203:1-3.
    >> Share

  133. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    >> Share

  134. WAGNER J, Agostoni P, Arena R, Belardinelli R, et al
    The Role of Gas Exchange Variables in Cardiopulmonary Exercise Testing for Risk Stratification and Management of Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2018;202:116-126.
    >> Share

  135. CAINZOS-ACHIRICA M, Rebordosa C, Vela E, Cleries M, et al
    Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases.
    Am Heart J. 2018;202:76-83.
    >> Share

  136. LUK A, Groarke JD, Desai AS, Mahmood SS, et al
    First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization.
    Am Heart J. 2018 May 19. pii: S0002-8703(18)30152.
    >> Share

  137. AMBROSY AP, Bhatt AS, Stebbins AL, Wruck LM, et al
    Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) ran
    Am Heart J. 2018;199:97-104.
    >> Share

  138. VAN SPALL HGC, Lee SF, Xie F, Ko DT, et al
    Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial.
    Am Heart J. 2018;199:75-82.
    >> Share

  139. PICCINI JP, Connolly SJ, Abraham WT, Healey JS, et al
    A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    Am Heart J. 2018;199:51-58.
    >> Share

  140. AMBROSY AP, Velazquez EJ
    Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.
    Am Heart J. 2018;199:176-177.
    >> Share

  141. JANUZZI JL, Butler J, Fombu E, Maisel A, et al
    Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
    Am Heart J. 2018;199:130-136.
    >> Share

  142. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    >> Share

  143. AJAM T, Ajam S, Devaraj S, Mohammed K, et al
    Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
    Am Heart J. 2018;199:1-6.
    >> Share

  144. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    >> Share

    April 2018
  145. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    >> Share

  146. GODOWN J, Smith AH, Thurm C, Hall M, et al
    Mechanical circulatory support costs in children bridged to heart transplantation - analysis of a linked database.
    Am Heart J. 2018;201:77-85.
    >> Share

  147. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    >> Share

  148. VELAZQUEZ EJ, Morrow DA, DeVore AD, Ambrosy AP, et al
    Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Am Heart J. 2018;198:145-151.
    >> Share

  149. KHAZANIE P, Hellkamp AS, Fonarow GC, Curtis LH, et al
    Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry.
    Am Heart J. 2018;198:123-128.
    >> Share

  150. EGBE A, Khan AR, Al-Otaibi M, Said SM, et al
    Outcomes of hospitalization in adults with Fontan palliation: The Mayo Clinic experience.
    Am Heart J. 2018;198:115-122.
    >> Share

    March 2018
  151. SULLIVAN LT 2ND, Randolph T, Merrill P, Jackson LR 2nd, et al
    Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction.
    Am Heart J. 2018;197:43-52.
    >> Share

    February 2018
  152. VAN BOVEN N, Battes LC, Akkerhuis KM, Rizopoulos D, et al
    Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study.
    Am Heart J. 2018;196:36-48.
    >> Share

    January 2018
  153. MANGLA A, Doukky R, Richardson D, Avery EF, et al
    Design of a bilevel clinical trial targeting adherence in heart failure patients and their providers: The Congestive Heart Failure Adherence Redesign Trial (CHART).
    Am Heart J. 2018;195:139-150.
    >> Share

    December 2017
  154. DA ROSA PR, Rohde LE, Doebber M, Ribeiro ALP, et al
    Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial.
    Am Heart J. 2017;194:125-131.
    >> Share

    November 2017
  155. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    >> Share

    October 2017
  156. CERBIN LP, Ambrosy AP, Mentz RJ
    Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction.
    Am Heart J. 2017;192:e3.
    >> Share

  157. TAYLOR R, Dalal H, Davies R, Doherty P, et al
    Cardiac rehabilitation in heart failure with reduced ejection fraction: A "should take it and not leave it" intervention.
    Am Heart J. 2017;192:e1-e2.
    >> Share

  158. GAGGIN HK, Chen-Tournoux AA, Christenson RH, Doros G, et al
    Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
    Am Heart J. 2017;192:26-37.
    >> Share

  159. ADIR Y, Guazzi M, Offer A, Temporelli PL, et al
    Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities.
    Am Heart J. 2017;192:120-127.
    >> Share

    September 2017
  160. SHERWOOD A, Hill LK, Blumenthal JA, Adams KF Jr, et al
    Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure.
    Am Heart J. 2017;191:82-90.
    >> Share

  161. LUO N, Teng TK, Tay WT, Anand IS, et al
    Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure.
    Am Heart J. 2017;191:75-81.
    >> Share

  162. FRIEDMAN DJ, Al-Khatib SM, Zeitler EP, Han J, et al
    New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Am Heart J. 2017;191:21-29.
    >> Share

    August 2017
  163. AUSTIN CO, Landolfo K, Parikh PP, Patel PC, et al
    Retained cardiac implantable electronic device fragments are not associated with magnetic resonance imaging safety issues, morbidity, or mortality after orthotopic heart transplant.
    Am Heart J. 2017;190:46-53.
    >> Share

  164. GIMPELEWICZ C, Metra M, Cleland JGF, Szecsody P, et al
    Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial.
    Am Heart J. 2017;190:113-122.
    >> Share

    July 2017
  165. RANDOLPH TC, Hellkamp AS, Zeitler EP, Fonarow GC, et al
    Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes.
    Am Heart J. 2017;189:48-58.
    >> Share

  166. HARIKRISHNAN S, Sanjay G, Agarwal A, Kumar NP, et al
    One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India.
    Am Heart J. 2017;189:193-199.
    >> Share

  167. DEVORE AD, Thomas L, Albert NM, Butler J, et al
    Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry.
    Am Heart J. 2017;189:177-183.
    >> Share

  168. CUNNINGHAM JW, Nathan AS, Rhodes J, Shafer K, et al
    Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation.
    Am Heart J. 2017;189:184-192.
    >> Share

    June 2017
  169. TER MAATEN JM, Maggioni AP, Latini R, Masson S, et al
    Clinical and prognostic value of spot urinary creatinine in chronic heart failure-An analysis from GISSI-HF.
    Am Heart J. 2017;188:189-195.
    >> Share

    Prognostication on the spot! The evolving importance of urinary creatinine in heart failure.
    Am Heart J. 2017;188:186-188.
    >> Share

  171. GOLDBERG SL, Meredith I, Marwick T, Haluska BA, et al
    A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR study.
    Am Heart J. 2017;188:167-174.
    >> Share

  172. RASLAN IR, Brown P, Westerhout CM, Ezekowitz JA, et al
    Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score.
    Am Heart J. 2017;188:127-135.
    >> Share

  173. VUKADINOVIC D, Lavall D, Vukadinovic AN, Pitt B, et al
    True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.
    Am Heart J. 2017;188:99-108.
    >> Share

  174. MOGENSEN UM, Kober L, Kristensen SL, Jhund PS, et al
    The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Am Heart J. 2017;188:35-41.
    >> Share

  175. JOHANSEN ND, Biering-Sorensen T, Jensen JS, Mogelvang R, et al
    Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events.
    Am Heart J. 2017;188:136-146.
    >> Share

    May 2017
  176. PANG PS, Teerlink JR, Boer-Martins L, Gimpelewicz C, et al
    Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial.
    Am Heart J. 2017;187:62-69.
    >> Share

    April 2017
  177. BAEZA-TRINIDAD R, Mosquera-Lozano JD
    Bendopnea: The next prognostic marker of advanced heart failure?
    Am Heart J. 2017;186:e1.
    >> Share

  178. ECHOUFFO-TCHEUGUI JB, Bishu KG, Fonarow GC, Egede LE, et al
    Trends in health care expenditure among US adults with heart failure: The Medical Expenditure Panel Survey 2002-2011.
    Am Heart J. 2017;186:63-72.
    >> Share

  179. AMBROSY AP, Cerbin LP, DeVore AD, Greene SJ, et al
    Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial.
    Am Heart J. 2017;186:130-138.
    >> Share

  180. FLINT K
    Cardiac rehabilitation in heart failure with reduced ejection fraction: A "take it or leave it" intervention.
    Am Heart J. 2017;186:127-129.
    >> Share

    March 2017
  181. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    >> Share

  182. REEVES GR, Whellan DJ, Duncan P, O'Connor CM, et al
    Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.
    Am Heart J. 2017;185:130-139.
    >> Share

  183. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    >> Share

  184. ROBINSON VM, Bharucha DB, Mahaffey KW, Dorian P, et al
    Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Am Heart J. 2017;185:43-51.
    >> Share

  185. BARRIOS D, Morillo R, Lobo JL, Nieto R, et al
    Assessment of right ventricular function in acute pulmonary embolism.
    Am Heart J. 2017;185:123-129.
    >> Share

  186. HORNE BD, Budge D, Masica AL, Savitz LA, et al
    Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization.
    Am Heart J. 2017;185:101-109.
    >> Share

  187. RICCI F, Mele D, Bianco F, Bucciarelli V, et al
    Right heart-pulmonary circulation unit and cardiac resynchronization therapy.
    Am Heart J. 2017;185:1-16.
    >> Share

    February 2017
  188. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    >> Share

    January 2017
  189. VERMA AK, Schulte PJ, Bittner V, Keteyian SJ, et al
    Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes.
    Am Heart J. 2017;183:54-61.
    >> Share

  190. COX ZL, Lewis CM, Lai P, Lenihan DJ, et al
    Validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center.
    Am Heart J. 2017;183:40-48.
    >> Share

  191. NAGARAJAN V, Hernandez AV, Cauthen CA, Starling RC, et al
    Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure.
    Am Heart J. 2017;183:35-39.
    >> Share

  192. STEINHAUS DA, Mostofsky E, Levitan EB, Dorans KS, et al
    Chocolate intake and incidence of heart failure: Findings from the Cohort of Swedish Men.
    Am Heart J. 2017;183:18-23.
    >> Share

  193. THIBODEAU JT, Jenny BE, Maduka JO, Divanji PH, et al
    Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure.
    Am Heart J. 2017;183:102-107.
    >> Share

    December 2016
  194. ECHOUFFO-TCHEUGUI JB, Xu H, DeVore AD, Schulte PJ, et al
    Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry.
    Am Heart J. 2016;182:9-20.
    >> Share

  195. SPITZER E, Van Mieghem NM, Pibarot P, Hahn RT, et al
    Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial.
    Am Heart J. 2016;182:80-88.
    >> Share

    November 2016
  196. LEE DS, Lee JS, Schull MJ, Grimshaw JM, et al
    Design and rationale for the Acute Congestive Heart Failure Urgent Care Evaluation: The ACUTE Study.
    Am Heart J. 2016;181:60-65.
    >> Share

  197. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    >> Share

    September 2016
  198. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    >> Share

  199. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    >> Share

  200. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    >> Share

  201. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    >> Share

    July 2016
  202. PEGUERO JG, Lo Presti S, Issa O, Podesta C, et al
    Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2.
    Am Heart J. 2016;177:153-9.
    >> Share

  203. KIM EJ, Yin X, Fontes JD, Magnani JW, et al
    Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).
    Am Heart J. 2016;177:138-44.
    >> Share

  204. BAKKESTROM R, Larsen LA, Moller JE, Videbaek L, et al
    Mitral valve regurgitation in twins: Concordance and survival.
    Am Heart J. 2016;177:51-7.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016